GlassScriptPhysician profile
Deirdre L Schwartz
NPI 1598899270
$3,003.07
in general payments reported to CMS, 2019-2025
30 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $956 · 2022: $570 · 2023: $654 · 2024: $666 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,476.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $433.40 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $308.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $237.44 | 2021-2024 | |
| Pfizer INC. | $200.74 | 2021-2024 | |
| Lilly USA, LLC | $192.16 | 2022-2025 | Jardiance, Mounjaro, Trulicity |
| Merck Sharp & Dohme LLC | $170.35 | 2021-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Glaxosmithkline, LLC. | $168.00 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $151.86 | 2021-2023 | |
| Amgen INC. | $136.81 | 2021-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $112.31 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $92.60 | 2022-2025 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $91.23 | 2021-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.67 | 2021-2023 | Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $69.18 | 2022-2023 | |
| Biogen, INC. | $62.64 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $58.83 | 2021-2022 | |
| Dexcom, INC. | $58.52 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $48.82 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $47.41 | 2021 | |
| Exact Sciences Corporation | $44.18 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.03 | 2024 | Xifaxan |
| Astellas Pharma US INC | $36.29 | 2021 | |
| Phathom Pharmaceuticals, INC. | $29.95 | 2024 | Voquezna |
| Alexion Pharmaceuticals, INC. | $27.71 | 2021 | |
| Idorsia Pharmaceuticals US INC | $22.12 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $21.87 | 2021 | |
| Shield Therapeutics INC | $19.51 | 2024 | |
| Covis Pharma Gmbh | $17.40 | 2022 | |
| Metacel Pharmaceuticals LLC | $16.25 | 2023 | Ozobax |
| Sanofi Pasteur INC. | $14.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deirdre Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.